Optimizing proinsulin production in E. coli BL21 (DE3) using taguchi method and efficient one-step insulin purification by on-column enzymatic cleavage
- PMID: 39847212
- PMCID: PMC11885722
- DOI: 10.1007/s42770-025-01614-z
Optimizing proinsulin production in E. coli BL21 (DE3) using taguchi method and efficient one-step insulin purification by on-column enzymatic cleavage
Abstract
Diabetes is a critical worldwide health problem. Numerous studies have focused on producing recombinant human insulin to address this issue. In this research, the process factors of production of recombinant His-tagged proinsulin in E. coli BL21 (DE3) strain were studied. Bacterial culture factors with significant effects on the amount of produced recombinant proinsulin were screened using a Taguchi L8 orthogonal array. Proinsulin expression was conducted under predicted optimal conditions. The folded impure His-tagged proinsulin was purified using immobilized metal ion affinity chromatography (IMAC). A novel IMAC sequence order combined with the use of non-His-tagged C-peptide cleavage enzymes followed by His- tagged enterokinase enzyme enabled simultaneous protein purification and elimination of C-peptide and His-tag in just one step. Statistical analysis revealed that the amount of produced proinsulin was significantly affected by several factors including the post-induction incubation temperature, Isopropyl ß-D-1-thiogalactopyranoside (IPTG) concentration, pre-induction incubation temperature, the glucose concentration, bacterial cell population at induction step, and the time of harvesting. The optimized model resulted in an empirical maximum proinsulin concentration of 254.5 ± 11.7 µg/ml. The high purity of the purified insulin (> 96% by SDS-PAGE) indicated that applied IMAC sequence order could be considered an efficient technique for on-column cleavage and insulin purification.
Keywords: Ion metal affinity chromatography (IMAC); On-column cleavage; Optimization; Recombinant proinsulin; Recombinant protein expression; Tag removal; Taguchi method.
© 2025. The Author(s) under exclusive licence to Sociedade Brasileira de Microbiologia.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare that there are no conflicts of interest.
References
-
- Bhoria S, Yadav J, Yadav H, Chaudhary D, Jaiwal R, Jaiwal PK (2022) Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus. Biotech Lett 44:643–669. 10.1007/s10529-022-03247-w - PubMed
-
- Dodson G, Steiner D (1998) The role of assembly in insulin’s biosynthesis. Curr Opin Struct Biol 8:189–194. 10.1016/s0959-440x(98)80037-7 - PubMed
-
- Govender T, Naicker T (2023) Insulin as a catalyst to recombinant DNA technology. Nat Catal 6:454–455. 10.1038/s41929-023-00976-7
-
- Najjar SM, Caprio S, Gastaldelli A (2023) Insulin Clearance in Health and Disease. Annu Rev Physiol 85:363–381. 10.1146/annurev-physiol-031622-043133 - PubMed
-
- Vaidyanathan J, Wang YMC, Tran D, Seo SK (2023) Leveraging clinical pharmacology data to assess biosimilarity and interchangeability of insulin products. Clin Pharmacol Ther 113:794–802. 10.1002/cpt.2731 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources